Eisai shares long-term data on lecanemab at neurology congress

48-month analysis shows delayed progression and reduced risk in early Alzheimer’s patients

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab at the 98th Congress of the German Society of Neurology in Berlin.

The analysis focused on adult patients with early Alzheimer’s disease who are apolipoprotein E ε4 non-carriers or heterozygotes.

Participants who received treatment from the start through to 48 months (n=409) continued to accrue benefit over time, with sustained separation from the Alzheimer’s Disease…